Literature DB >> 8383805

Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos.

P Gressens1, J M Hill, I Gozes, M Fridkin, D E Brenneman.   

Abstract

Factors controlling central nervous system (CNS) growth immediately after neurulation are mostly unknown. Vasoactive intestinal peptide (VIP) receptors are widely distributed in the embryonic nervous system, and VIP has trophic and mitogenic properties on embryonic neural tissues but inhibits growth and mitosis in certain tumours. To address the potential effects of VIP on embryonic growth, we used whole postimplantation embryo cultures. After a 4-h incubation, VIP stimulated growth, increasing somite number, embryonic volume, DNA and protein content, and number of cells in S-phase. A VIP antagonist substantially inhibited these VIP-mediated increments in growth. The VIP antagonist completely suppressed VIP-stimulated mitosis in the CNS while decreasing the same in non-neuronal tissues by 38%. In vitro autoradiography revealed GTP-sensitive and GTP-insensitive VIP receptors which were differentially regulated in VIP antagonist-treated embryos. The present study suggests that VIP acts as a growth factor on early postimplantation embryos through multiple VIP receptors that exhibit tissue-specific responses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383805     DOI: 10.1038/362155a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  36 in total

1.  Epithelial expression of vasoactive intestinal peptide in ulcerative colitis: down-regulation in markedly inflamed colon.

Authors:  Maria Jönsson; Orjan Norrgård; Sture Forsgren
Journal:  Dig Dis Sci       Date:  2011-12-06       Impact factor: 3.199

2.  Signaling through the neuropeptide GPCR PAC₁ induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor.

Authors:  Andrew C Emery; Lee E Eiden
Journal:  FASEB J       Date:  2012-04-24       Impact factor: 5.191

3.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

4.  Molecular atherectomy for restenosis.

Authors:  W Casscells; D A Lappi; A Baird
Journal:  Trends Cardiovasc Med       Date:  1993 Nov-Dec       Impact factor: 6.677

5.  VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Authors:  Sandrine Passemard; Vincent El Ghouzzi; Hala Nasser; Catherine Verney; Guilan Vodjdani; Adrien Lacaud; Sophie Lebon; Marc Laburthe; Patrick Robberecht; Jeannette Nardelli; Shyamala Mani; Alain Verloes; Pierre Gressens; Vincent Lelièvre
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

Review 6.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

7.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.

Authors:  P Gressens; J M Hill; B Paindaveine; I Gozes; M Fridkin; D E Brenneman
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.

Authors:  Christine Dufes; Céline Alleaume; Alicia Montoni; Jean-Christophe Olivier; Jean-Marc Muller
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

9.  The gene for the neuropeptide gonadotropin-releasing hormone is expressed in the mammary gland of lactating rats.

Authors:  A Palmon; N Ben Aroya; S Tel-Or; Y Burstein; M Fridkin; Y Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

10.  Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.

Authors:  Eliezer Giladi; Joanna M Hill; Efrat Dresner; Conor M Stack; Illana Gozes
Journal:  J Mol Neurosci       Date:  2007-10-02       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.